These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 24359499)

  • 1. The Utility of Chemotherapy in the Treatment of Metastatic Prostate Cancer.
    Gupta K; Elkon J; El-Bahesh E; Aragon-Ching JB
    Anticancer Agents Med Chem; 2016; 16(9):1166-71. PubMed ID: 24359499
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment decisions for metastatic castration-resistant prostate cancer progressing after docetaxel chemotherapy: the role of cabazitaxel in the continuum of care.
    Heidenreich A; Pfister D
    Eur Urol; 2012 Dec; 62(6):1201-4. PubMed ID: 22964168
    [No Abstract]   [Full Text] [Related]  

  • 3. Should docetaxel be administered earlier in prostate cancer therapy?
    Graff JN; Beer TM
    Expert Rev Anticancer Ther; 2015; 15(9):977-9. PubMed ID: 26223224
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cabazitaxel for Hormone-Relapsed Metastatic Prostate Cancer Previously Treated With a Docetaxel-Containing Regimen: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
    Kearns B; Pandor A; Stevenson M; Hamilton J; Chambers D; Clowes M; Graham J; Kumar MS
    Pharmacoeconomics; 2017 Apr; 35(4):415-424. PubMed ID: 27770303
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Metastatic castration-resistant prostate cancer: changing landscape with cabazitaxel.
    Fernández O; Afonso J; Vázquez S; Campos B; Lázaro M; León L; Antón Aparicio LM
    Anticancer Drugs; 2014 Mar; 25(3):237-43. PubMed ID: 24217332
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Will chemotherapy change the management of prostate cancer?
    Gilson C; Sydes MR; Chowdhury S
    BJU Int; 2016 Aug; 118(2):190-2. PubMed ID: 26696125
    [No Abstract]   [Full Text] [Related]  

  • 7. Current status of cytotoxic chemotherapy in patients with metastatic prostate cancer.
    Dreicer R
    Urol Oncol; 2008; 26(4):426-9. PubMed ID: 18593622
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Optimizing the use of docetaxel in men with castration-resistant metastatic prostate cancer.
    Armstrong AJ; George DJ
    Prostate Cancer Prostatic Dis; 2010 Jun; 13(2):108-16. PubMed ID: 20066005
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Metastatic prostate cancer : Update: position paper for the use of chemotherapy].
    Ohlmann CH; Goebell PJ; Grimm MO; Klier J; König F; Machtens S; Schostak M; Schrader AJ; Albers P
    Urologe A; 2017 Dec; 56(12):1597-1602. PubMed ID: 28695241
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cabazitaxel: more than a new taxane for metastatic castrate-resistant prostate cancer?
    Mita AC; Figlin R; Mita MM
    Clin Cancer Res; 2012 Dec; 18(24):6574-9. PubMed ID: 23091116
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Cabazitaxel after docetaxel: a new option in metastatic castration-resistant prostate cancer].
    Lheureux S; Joly F
    Bull Cancer; 2012 Sep; 99(9):875-80. PubMed ID: 22877855
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Role of second-line systemic treatment post-docetaxel in metastatic castrate resistant prostate cancer- current strategies and future directions.
    Ansari J; Hussain SA; Alhasso A; Mahmood R; Ansari A; Glaholm J
    Anticancer Agents Med Chem; 2011 Mar; 11(3):296-306. PubMed ID: 21426298
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cabazitaxel for the treatment of prostate cancer.
    Michielsen DP; Braeckman JG; Denis L
    Expert Opin Pharmacother; 2011 Apr; 12(6):977-82. PubMed ID: 21406025
    [TBL] [Abstract][Full Text] [Related]  

  • 14. 'Charting a new course for prostate cancer' - currying favor for docetaxel in hormone-sensitive metastatic prostate cancer.
    Voskoboynik M; Staffurth J; Malik Z; Sweeney C; Chowdhury S
    Expert Rev Anticancer Ther; 2014 Nov; 14(11):1253-6. PubMed ID: 25353342
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cabazitaxel for the treatment of castration-resistant prostate cancer.
    Agarwal N; Sonpavde G; Sartor O
    Future Oncol; 2011 Jan; 7(1):15-24. PubMed ID: 21174534
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Optimal timing of chemotherapy in androgen independent prostate cancer.
    Schnadig ID; Beer TM
    Urol Oncol; 2009; 27(1):97-100. PubMed ID: 19111808
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Docetaxel for hormone-sensitive metastatic prostate cancer.
    Baker H
    Lancet Oncol; 2015 Sep; 16(9):e432. PubMed ID: 26278160
    [No Abstract]   [Full Text] [Related]  

  • 18. Cabazitaxel for metastatic hormone-relapsed prostate cancer treated with docetaxel.
    Lovett R; Kelly V; Goodall M; Adler AI
    Lancet Oncol; 2016 Jul; 17(7):872-873. PubMed ID: 27234583
    [No Abstract]   [Full Text] [Related]  

  • 19. Expert opinion on chemotherapy use in castration-resistant prostate cancer progressing after docetaxel.
    Gallardo E; Arranz JÁ; Maroto JP; León LÁ; Bellmunt J
    Crit Rev Oncol Hematol; 2013 Nov; 88(2):357-67. PubMed ID: 23867574
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Re: Axel Heidenreich, David Pfister. Treatment decisions for metastatic castration-resistant prostate cancer progressing after docetaxel chemotherapy: the role of cabazitaxel in the continuum of care. Eur Urol 2012;62:1201-4.
    Brookman-May S; Tombal B; Joniau S
    Eur Urol; 2013 Sep; 64(3):e62-4. PubMed ID: 23582882
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.